EyePoint, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
5.32
-0.08 (-1.48%)
At close: Aug 21, 2026, 4:00 PM EDT
5.30
-0.02 (-0.38%)
After-hours: Aug 21, 2026, 7:57 PM EDT
EyePoint Employees
EyePoint had 214 employees as of December 31, 2025. The number of employees increased by 49 or 29.70% compared to the previous year.
Employees
214
Change (1Y)
49
Growth (1Y)
29.70%
Revenue / Employee
$13,028
Profits / Employee
-$1,432,911
Market Cap
458.65M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 214 | 49 | 29.70% | 214 | 0 |
| Dec 31, 2024 | 165 | 44 | 36.36% | 165 | 0 |
| Dec 31, 2023 | 121 | -23 | -15.97% | 121 | 0 |
| Dec 31, 2022 | 144 | 21 | 17.07% | 144 | 0 |
| Dec 31, 2021 | 123 | 22 | 21.78% | 122 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 485 |
| Puma Biotechnology | 179 |
| Ocugen | 116 |
| Editas Medicine | 87 |
| Rezolute | 68 |
| Prothena Corporation | 67 |
| Eupraxia Pharmaceuticals | 49 |
| Q32 Bio | 22 |
EYPT News
- 3 days ago - EyePoint price target lowered to $20 from $43 at Jones - TheFly
- 4 days ago - EyePoint downgraded to Neutral from Buy at Chardan - TheFly
- 4 days ago - EyePoint downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 4 days ago - EyePoint price target lowered to $17 from $35 at Citi - TheFly
- 4 days ago - EyePoint downgraded to Sector Perform from Outperform at RBC Capital - TheFly
- 4 days ago - EyePoint downgraded to Sector Perform from Outperform at RBC Capital - TheFly
- 5 days ago - Clear Street sees less competition for Ocular after EyePoint miss - TheFly
- 5 days ago - Laidlaw trims EyePoint target, still sees high chance of approval - TheFly